ReviewReviews in endocrine & metabolic disorders2018
Supportive therapy in gastroenteropancreatic neuroendocrine tumors: Often forgotten but important.
Review in Reviews in endocrine & metabolic disorders, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 15 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
15 citing papers in PubMed, 38 citations in OpenAlex.
- Neuroendocrine tumours through an epigenetic lens: Emerging insights for diagnosis and treatment.Journal of neuroendocrinology · 2026Review
- A prediction tool for malnutrition and sarcopenia in patients with gastroenteropancreatic neuroendocrine neoplasms: results from NUTRIGETNE (GETNE-S2109) study.Frontiers in nutrition · 2026Article
- Controversies in NEN: An ENETS position statement on nutritional support in neuroendocrine neoplasms.Journal of neuroendocrinology · 2025Review
- Endocrine paraneoplastic syndromes in lung cancer: A call for clinical vigilance (Review).Molecular and clinical oncology · 2025Review
- Nutritional status and quality of life of patients with advanced gastroenteropancreatic neuroendocrine neoplasms in Spain: the NUTRIGETNE (GETNE-S2109) study.The oncologist · 2025Article
- Practical considerations when providing palliative care to patients with neuroendocrine tumors in the context of routine disease management or hospice care.Endocrine-related cancer · 2023Review
- Value of a preoperative prognostic nutritional index for the prognostic evaluation of gastric neuroendocrine carcinoma patients.Frontiers in nutrition · 2023Article
- The overriding role of surgery and tumor grade for long-term survival in patients with gastroenteropancreatic neuroendocrine neoplasms: A population-based cohort study.Cancer reports (Hoboken, N.J.) · 2022Observational
- Glucagonoma: From skin lesions to the neuroendocrine component (Review).Experimental and therapeutic medicine · 2020Review
- Assessment and State of Nutrition of Patients with Gastroenteropancreatic Neuroendocrine Neoplasms.Nutrients · 2020Article
- The Neuroendocrine Neoplasms of the Digestive Tract: Diagnosis, Treatment and Nutrition.Nutrients · 2020Review
- Inhibition of Wnt/β-Catenin Signaling in Neuroendocrine Tumors in vitro: Antitumoral Effects.Cancers · 2020Article
- Carcinoid Syndrome: Updates and Review of Current Therapy.Current treatment options in oncology · 2019Review
- Nutrition and neuroendocrine tumors: An update of the literature.Reviews in endocrine & metabolic disorders · 2018Review
- Neuroendocrine neoplasms - think about it and choose the most appropriate diagnostic and therapeutic steps.Reviews in endocrine & metabolic disorders · 2018Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Neuroendocrine tumors (NETs) are a group of rare and heterogeneous malignancies that can develop in various organs. A significant number of gastroenteropancreatic neuroendocrine tumours (GEP-NETs) is functionally active and presents with symptoms related to the secretion of biologically active substances, leading to the development of distinct clinical syndromes. There are various therapeutic approaches for GEP-NETs, including curative surgery, palliative surgery, local-ablative and loco-regional therapies as well as systemic therapeutic options including peptide receptor radionuclide therapy, cytotoxic therapy, and molecularly targeted therapies. Specific supportive therapy of patients with NETs includes management or prevention of hormone-related clinical syndromes and paraneoplastic states. Supportive therapy plays a key role in NET treatment. Supportive therapy includes debulking surgery and interventional radiologic techniques to reduce tumour bulk or load, as well as systemic medical treatment options to manage or prevent hypersecretion syndromes and treatment-related side effects. Supportive therapies are a type of of comprehensive treatment addressing the patient as a whole person throughout the process of NET treatment. Therefore, supportive therapy also encompasses psychosocial support, expert nursing, nutritional support and management of cancer related pain.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.